GCM
NTLA icon

Goldstream Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Goldstream Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,500
Closed -$476K – 24
2022
Q3 		$476K Buy
8,500
+4,500
+113% +$279K 0.37% 9
2022
Q2 		$207K Buy
+4,000
New +$203K 0.18% 10
2022
Q1 		– Sell
-30,161
Closed -$3.57M – 37
2021
Q4 		$3.57M Buy
+30,161
New +$3.78M 0.88% 10

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Goldstream Capital Management's NTLA Position: Q4 2022 in Review

Goldstream Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 8,500 shares — an estimated $476K sold.

Goldstream Capital Management first reported a position in NTLA in Q4 2021 and held it in 3 quarters. The position peaked at $3.57M in Q4 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Goldstream Capital Management reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Goldstream Capital Management sold 8,500 Intellia Therapeutics shares in Q4 2022, an estimated $476K.
  • Goldstream Capital Management first reported a position in Intellia Therapeutics in Q4 2021 and held it in 3 quarters.
  • Goldstream Capital Management's Intellia Therapeutics position peaked at $3.57M in Q4 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Goldstream Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.